

Stahl's Illustrated

Index

- acetylcholine (ACh) *see*
 - muscarinic receptors
- affective symptoms 3, 32, 33
- aggressive symptoms 3, 144
- α 1-adrenergic receptors 96, 97
 - antipsychotic binding
 - profiles 142, 143
- α 2-adrenergic receptors 128, 129
- Alzheimer's disease *see* dementia
- amisulpride 120, 121
- AMPA receptors 6, 7, 40
- antipsychotics 98, 111
 - agonist/antagonist spectrum
 - 99, 106, 107
 - receptor binding profiles
 - 109, 122, 143
 - see also individual drugs*
- aripiprazole 174, 175
 - receptor binding profile
 - 122, 143
 - switching strategies 192, 194
- aripiprazole LAI formulations
 - aripiprazole lauroxil 204
 - aripiprazole lauroxil nanocrystal
 - dispersion 205
 - aripiprazole monohydrate 203
 - 2 monthly 206
- arousal pathways 97
- asenapine 152, 153
 - receptor binding profile 122, 143
- switching strategies 187,
 - 191, 193
- atypical antipsychotics *see* second-generation antipsychotics
- β -arrestin 12, 13
- blonanserin 172, 173
- brexpiprazole 176, 177
 - receptor binding profile
 - 122, 143
- cariprazine 178, 179
 - receptor binding profile
 - 122, 143
- chlorpromazine 112, 113
- cholinergic circuit *see*
 - muscarinic receptors
- clozapine 144, 145
 - receptor binding profile
 - 122, 143
 - switching strategies 187,
 - 191, 193
- cognitive symptoms 3, 32, 33
- cross-titration 185, 186
- CSTC loop 27, 29
 - overactive go signal 86,
 - 87, 90, 91
 - stop pathway activation 84, 85
 - stop pathway inhibition 82, 83
 - VMAT2 inhibition 92, 95

- DA *see* dopamine
- delusions 1, 16, 17
- dementia
 - future treatments 209
 - glutamate 43, 46, 47
 - serotonin 5HT_{2A} receptors 60, 61, 66, 67
- deutetrabenazine 89
- disorders featuring psychosis 19
 - see also* schizophrenia
- dopamine (DA)
 - dopamine hypothesis of psychosis 21, 30, 33
 - and glutamate 11, 14, 15
 - and M₁ receptors 10, 11, 77, 79, 210, 213
 - and M₄ receptors 10, 11, 214, 215
 - motor control 27, 29, 75, 76, 78, 79, 82, 87, 90, 91
 - pathways 22
 - postsynaptic receptors 25
 - presynaptic receptors 1, 26
 - and prolactin 104
 - and serotonin 5HT_{1A} receptors 108
 - and serotonin 5HT_{2A} receptors 16, 17, 100, 103
 - short form D₂ receptor 9
 - synthesis 8, 23
 - termination 24
 - and trace amines/TAAR1 12, 13, 219, 220
 - and VMAT2 88, 89
- dopamine 2 antagonists/
 - partial agonists
- cholinergic system 78, 79
- 1st-generation antipsychotics 70, 112, 121
- mesocortical pathway 73
- mesolimbic pathway 71
- nigrostriatal pathway 75, 76, 84, 87
- prolactin levels 74, 105
- spectrum of activity 99, 106, 107
- tuberoinfundibular pathway 74
- dopamine 3 receptors 130, 131
- drug-induced parkinsonism 75, 76, 78, 79, 84, 85
- drugs of abuse 56, 57, 62, 63
- emraclidine 209, 217
- epigenetics 4, 5
- first-generation antipsychotics 112
 - 5-hydroxytryptamine (5HT) *see* serotonin
- fluphenazine 114, 115
- fluphenazine decanoate 196
- future treatments 209
 - M₁ receptor modulation 210, 213, 216
 - M₄ receptor modulation 214, 218
 - TAAR1 agonists 219, 220
- GABA (γ-aminobutyric acid)
 - interneurons 11, 42, 48, 49, 60, 61, 66, 67, 210, 213
- genetics 4, 5
- glutamate
 - and dementia 43, 46, 47, 60, 61, 66, 67
 - and dopamine 11, 14, 15
 - glutamate hypothesis of psychosis 21, 42, 49
 - and hallucinogens 56, 57, 62, 63
 - and M₁ receptors 210, 213
 - and Parkinson's disease 58, 59, 64, 65
 - pathways 34, 35

- glutamate (cont.)
 - receptors 38
 - AMPA 6, 7, 40
 - kainate 40
 - metabotropic 39
 - NMDA 6, 7, 14, 15, 41, 42, 44, 45, 48, 49
 - recycling/regeneration 36, 37
 - synaptogenesis 6, 7
- glycogen synthase kinase 3 (GSK-3) 12, 13
- gynecological side effects 74
- hallucinations 1, 16, 17, 46, 47
- hallucinogens 56, 57, 62, 63
- haloperidol 116, 117
- haloperidol decanoate 195
- histamine 1 receptors 96, 97
 - antipsychotic binding profiles 140, 141
- hyperkinesia (tardive dyskinesia) 76, 86, 87, 89, 95
- iloperidone 162, 163
 - receptor binding profile 122, 143
 - switching strategies 187, 190, 192, 194
- inhibitory G (Gi) protein 12, 13
- insulin resistance 110
- kainate receptors 40
- long-acting injectables (LAIs)
 - aripiprazole 2 monthly 206
 - aripiprazole lauroxil 204
 - aripiprazole lauroxil nanocrystal dispersion 205
 - aripiprazole monohydrate 203
 - fluphenazine decanoate 196
 - haloperidol decanoate 195
 - olanzapine pamoate 207
 - paliperidone palmitate 1
 - monthly 200
 - paliperidone palmitate 3
 - monthly 201
 - paliperidone palmitate 6
 - monthly 202
 - risperidone microspheres 197
 - risperidone monthly (Perseris) 198
 - risperidone monthly/2 monthly (Uzedly) 199
- lumateperone 166, 167
 - receptor binding profile 122, 143
 - switching strategies 187, 190, 192, 194
- lurasidone 164, 165
 - receptor binding profile 122, 143
 - switching strategies 187, 190, 192, 194
- magnesium 41
- mechanisms of action of
 - antipsychotics 70
- mesocortical DA pathway 22
 - and D2 antagonists/partial agonists 73
 - in schizophrenia 32, 33, 48, 49, 72
- mesolimbic DA pathway 14, 15, 21, 22, 30, 31, 44, 45, 47
 - and D2 antagonists/partial agonists 71
- mesostriatal DA pathway 31
- metabotropic glutamate
 - autoreceptors 39
- monoamine oxidase B (MAO-B) 24, 52
- monoamine transporters 126, 127
- motivation and reward
 - pathway 30, 31

- motor control
 - CSTC loop 27, 29, 82, 83
 - side effects of D2 antagonists/
partial agonists 75, 76,
78, 79, 84, 87, 89, 95
- muscarinic receptors
 - antipsychotic binding
 - profiles 140, 141
 - M1 and dopamine 10, 11,
77, 79, 210, 213
 - M1/M4 agonist 216
 - M4 agonist 218
 - M4 and dopamine 10,
11, 214, 215
 - M4 positive allosteric
modulator 217
 - side effects of M1 blockade
80, 81, 97
- natural history of
 - schizophrenia 18
- nature and nurture 4, 5
- NBI-1117568 (M4 agonist) 218
- negative symptoms 1, 2, 3,
32, 33, 48, 49
 - secondary 71, 73
- neurocircuits in psychosis
10, 17, 72
- neurodegeneration
 - in dementia 43, 46, 47
 - in schizophrenia 18
- neurodevelopmental
 - hypothesis 6, 7
- new developments see
future treatments
- nigrostriatal dopamine pathway
22, 27, 58, 59, 82, 83
 - and D2 antagonists/partial
agonists 75, 76, 84, 87
- NMDA glutamate receptors
6, 7, 14, 15, 41, 42,
44, 45, 48, 49
- norepinephrine 54, 55, 97
- norepinephrine transporter
(NET) 126, 127
- olanzapine 146, 147
 - receptor binding profile
122, 143
 - switching strategies 187,
191, 193
- olanzapine pamoate 207
- olanzapine-samidorphan
148, 149
- paliperidone 158, 159
 - receptor binding profile
122, 143
 - switching strategies 187,
190, 192, 194
- paliperidone palmitate
 - 1 monthly 200
 - 3 monthly 201
 - 6 monthly 202
- parkinsonism, drug-induced 75,
76, 78, 79, 84, 85
- Parkinson's disease
 - future treatments 209
 - and serotonin 5HT2A receptors
58, 59, 64, 65
- perospirone 170, 171
- pimavanserin 180, 181
- positive symptoms 1, 2, 3,
14, 17, 30, 31,
44, 47, 56, 67
- prefrontal cortex 3, 16, 17, 32,
33, 48, 49, 212, 213
- presynaptic dopamine
receptors 1, 26
- presynaptic glutamate
receptors 39
- presynaptic serotonin receptors 53
- prolactin 74, 104, 105

- quetiapine 150, 151
 - receptor binding profile 122, 143
 - switching strategies 187, 191, 193
- research see future treatments
- risperidone 156, 157
 - receptor binding profile 122, 143
 - switching strategies 187, 190, 192, 194
- risperidone LAI formulations
 - microspheres 197
 - monthly (Perseris) 198
 - monthly/2 monthly (Uzedy) 199
- schizophrenia
 - course 18
 - D2 receptor short form 9
 - dopamine hypothesis 30, 33
 - dopamine over-synthesis 8
 - future treatments 209, 220
 - glutamate hypothesis 44, 45, 48, 49
 - neurocircuits 10, 17, 72
 - pathogenesis 4, 7
 - symptoms 1, 3
- second-generation antipsychotics
 - blonanserin 172, 173
 - done class 156, 167
 - perospirone 170, 171
 - pimavanserin 180, 181
 - pine class 144, 155
 - pip/rip class 174, 179
 - receptor binding profiles 122, 143
 - sertindole 168, 169
 - switching see switching strategies
- sedation 97
- serotonin (5HT)
 - and dementia 60, 61, 66, 67
 - and dopamine 16, 17
 - and Parkinson's disease 58, 59, 64, 65
 - pathways 50
 - and prolactin 104
 - receptor subtypes 53
 - regulatory role 54, 55
 - synthesis 51
 - termination 52
- serotonin 5HT1A receptor 108
 - antipsychotic binding profiles 124, 125
- serotonin 5HT1B/5HT1D receptor 138, 139
- serotonin 5HT2A receptor
 - antipsychotic binding profiles 122, 123
 - and dementia 60, 61, 66, 67
 - and dopamine 16, 17, 100, 101
 - and hallucinogens 56, 57, 62, 63
 - and Parkinson's disease 58, 59, 64, 65
- serotonin 5HT2A receptor
 - antagonists 99, 102, 103
 - pimavanserin 181
 - and prolactin 105
- serotonin 5HT2A/D2 receptor
 - antagonists
 - blonanserin 172, 173
 - done class 156, 167
 - perospirone 170, 171
 - pine class 144, 155
 - sertindole 168, 169
- serotonin 5HT2C receptor 132, 133
- serotonin 5HT3 receptor 134, 135
- serotonin 5HT6/5HT7 receptors 136, 137
- serotonin transporter (SERT) 52, 126, 127
- sertindole 168, 169

- side effects 69, 109
 - amisulpride 121
 - aripiprazole 175
 - asenapine 153
 - blonanserin 173
 - brexpiprazole 177
 - cariprazine 179
 - chlorpromazine 113
 - clozapine 145
 - fluphenazine 115
 - haloperidol 117
 - histamine and $\alpha 1$ -adrenergic receptor blockade 96
 - hyperprolactinemia 74, 105
 - iloperidone 163
 - insulin resistance 110
 - lumateperone 167
 - lurasidone 165
 - motor symptoms 75, 76, 78, 79, 84, 87, 89, 95
 - muscarinic receptor blockade 80, 81, 97
 - negative symptoms 71, 73
 - olanzapine 147
 - olanzapine-samidorphan 149
 - paliperidone 159
 - perospirone 171
 - pimavanserin 181
 - quetiapine 151
 - risperidone 157
 - sedation 97
 - sertindole 169
 - sulpiride 119
 - ziprasidone 161
 - zotepine 155
- striatum 79, 210, 211
- suicide risk 144
- sulpiride 118, 119
- switching strategies 183
 - aripiprazole to done 194
 - aripiprazole to pine 193
 - cross-titration 185, 186
 - done to aripiprazole 192
 - done to pine 190
 - how not to 184
 - oral to LAI 195, 207
 - pine to aripiprazole 191
 - pine to done 188, 189
 - within-class 187
- symptoms 1, 3
 - see also negative symptoms; positive symptoms
- synaptogenesis, abnormal 6, 7, 18
- TAAR1 (trace amine-associated receptor 1) 12, 13, 219, 220
- tardive dyskinesia (TD) 76, 86, 87, 89, 95
- tetrabenazine-related drugs 89
- trace amines/TAAR1 12, 13, 219, 220
- trospium 216
- tryptophan 51
- tuberoinfundibular DA pathway 22, 74
- tyrosine 23
- ulotaront 209, 220
- valbenazine 89
- vesicular monoamine transporter 2 (VMAT2)
 - dopamine storage 88
 - inhibition 89, 92, 95
- xanomeline-trospium 209, 216
- ziprasidone 160, 161
 - receptor binding profile 122, 143
 - switching strategies 187, 190, 192, 194
- zotepine 154, 155
 - receptor binding profile 122, 143